Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

Pricing
Back to journals
Academic Journal

AJOB Neuroscience

2 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

This national survey (n=795) in the USA assesses public attitudes towards psilocybin use in licensed settings for psychiatric treatment and well-being enhancement. Participants from across the political spectrum overwhelmingly viewed the individual's decision as morally positive in both contexts, suggesting strong bipartisan support for supervised psilocybin use.

Published
February 5, 2024
Journal
AJOB Neuroscience
Authors
Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., Earp, B. D.
Open Accessmeta

Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias

This review (2022) investigates six ethical issues concerning psychedelic medicine and research involving persons living with Alzheimer's Disease (AD)/ADRD, including autonomy, consent, ego dissolution, caregiving, exploitation of patient desperation, and methods to mitigate inequity.

Published
December 8, 2022
Journal
AJOB Neuroscience
Authors
Peterson, A., Largent, E. A., Sisti, D., Karlawish, J., Lynch, H. F.

Quick Facts

Papers Indexed
2
h-Index
34
Open Access
No
Publisher
Taylor & Francis
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.